Women with a history of venous
thromboembolisms (
VTEs) and/or
thrombophilia are at increased risk of VTE during pregnancy. We analysed our cohort of such women who were treated with a prophylactic doses of
dalteparin. 152 pregnant women with 179 pregnancies were classified into 3 groups: (1) previous VTE without
thrombophilia (122 pregnancies); (2) previous VTE with
thrombophilia (26 pregnancies) and (3)
thrombophilia only (31 pregnancies). They were treated with prophylactic
dalteparin in the prepartum and postpartum periods or only in the postpartum period. Occurrences of symptomatic VTE and
bleeding episodes were followed, as well as
dalteparin discontinuation and anti-Xa activity. Symptomatic
deep vein thrombosis occurred in 4 women (2.2%) with 2 episodes in group 1 (in the postpartum period) and 2 episodes in group 2 (one in the prepartum and another in the postpartum period). Seven episodes (3.9%) of minor
bleeding occurred.
Dalteparin was not stopped in any women. Anti-Xa levels were within the prophylactic range. Our real-world data show a low incidence of
thrombosis and minor
bleeding in pregnant women treated with prophylactic
dalteparin. The incidence of recurrent VTE was lower than that reported in women with similar risk, but without prophylactic anticoagulation.